LITAF and metabolic dysfunction-associated steatotic liver disease: In conclusion, the discovery of LITAF as a key regulator of pro-inflammatory and pro-fibrogenic response in HSCs provides new insights in the molecular pathogenesis of NAFLD-related damage.